COMBINATION THERAPY FOR CANCER

The present invention relates to the field of medicine. More particularly, the present disclosure relates to combinations of an antibody that binds colony-stimulating factor 1 receptor (CSF-IR) and an antibody that binds human programmed cell death I ligand 1 (PD- Ll) and to methods of using the com...

Full description

Saved in:
Bibliographic Details
Main Author SCHAER, David Arlen
Format Patent
LanguageEnglish
French
Published 01.06.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the field of medicine. More particularly, the present disclosure relates to combinations of an antibody that binds colony-stimulating factor 1 receptor (CSF-IR) and an antibody that binds human programmed cell death I ligand 1 (PD- Ll) and to methods of using the combination to treat cancer, and in particular solid tumors with macrophage infiltration. La présente invention concerne le domaine de la médecine. Plus particulièrement, la présente invention concerne des combinaisons d'un anticorps qui se lie au récepteur du facteur 1 de stimulation des colonies (CSF-IR) et d'un anticorps qui se lie au ligand 1 de la protéine de la mort cellulaire programmée (PD-L1) et des procédés d'utilisation de cette combinaison pour traiter un cancer, et en particulier des tumeurs solides par l'infiltration de macrophages.
Bibliography:Application Number: WO2016US62401